Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days
The Lancet
4d

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a ...

oAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea ...
The Lancet
5d

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

Trump drops $10B IRS suit
Rare tornado threat issued
Acquitted of tax fraud
Cooper signs off '60 Minutes'
Thousands attend prayer rally
China to boost US agri trade
House explosion in Illinois
Dr. Hook singer dies at 76
To arrive in Netherlands
Oil prices rise
Drone hits UAE nuke plant site
Italian divers’ bodies found
Earthquake in China
Attacks on Nigeria schools
Signs 5-year deal with EDF
2 US jets collide mid-air
Austin shootings: Teens held
To unveil AI encyclical
HK court hears final arguments
Sinner wins Italian Open
Philippines opens VP trial
To buy Dominion Energy
Car crashes into crowd in CA
Rodgers agrees to 1-yr deal
Passenger bites crew member
McGregor to make UFC return
Bulgaria wins Eurovision
To skip Cannes Palme d’Or
Tops box office again
UKR drone strikes on RU
WHO declares Ebola emergency
Wins 2nd straight NBA MVP
Rai’s historic PGA victory
  • Privacy
  • Terms